{"id":"NCT01308580","sponsor":"Sanofi","briefTitle":"Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer","officialTitle":"Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2011-03-04","resultsPosted":"2016-10-11","lastUpdate":"2017-04-17"},"enrollment":1200,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Cabazitaxel (XRP6258)","otherNames":["Jevtana®"]},{"type":"DRUG","name":"Prednisone (or Prednisolone)","otherNames":[]}],"arms":[{"label":"Cabazitaxel 20 mg/m^2","type":"EXPERIMENTAL"},{"label":"Cabazitaxel 25 mg/m^2","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\n\\- To demonstrate the non inferiority in term of overall survival (OS) of Cabazitaxel 20 mg/m² (Arm A) versus Cabazitaxel 25 mg/m² (Arm B) in combination with prednisone in participants with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen.\n\nSecondary Objectives:\n\n* To evaluate safety in the 2 treatment arms and to assess if Cabazitaxel 20 mg/m² was better tolerated than Cabazitaxel 25 mg/m².\n* To compare efficacy of Cabazitaxel at 20 mg/m² and 25 mg/m² for:\n\n  * Progression Free Survival (PFS) defined as the first occurrence of any of the following events: tumor progression per Response Evaluation Criteria In Solid Tumors (RECIST), prostate-specific antigen (PSA) progression, pain progression or death due to any cause;\n  * PSA Progression;\n  * Pain progression;\n  * Tumor response in participants with measurable disease (RECIST 1.1);\n  * PSA response;\n  * Pain response in participants with stable pain at baseline.\n* To compare Health-related Quality of Life (HRQoL).\n* To assess the pharmacokinetics and pharmacogenomics of Cabazitaxel.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From baseline up to death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)","effectByArm":[{"arm":"Cabazitaxel 20 mg/m^2","deltaMin":13.4,"sd":null},{"arm":"Cabazitaxel 25 mg/m^2","deltaMin":14.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":172,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","France","Germany","Hungary","Netherlands","Peru","Poland","Romania","Russia","South Africa","South Korea","Spain","Taiwan","Tunisia","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["35677318","33740734","29500065","28809610","23228299"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":177,"n":580},"commonTop":["Diarrhoea","Nausea","Fatigue","Constipation","Asthenia"]}}